Bausch Health Companies Inc.
BHC
5.38 EUR
1 Tag: -3.23% (-0.18 EUR)
Der Alarm wird direkt gespeichert, ohne auf die Homepage zu springen.
Kursalarme fuer BHC
Bitte anmelden, um Kursalarme zu sehen und zu speichern.
Finanzen
Unternehmensinfo
Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company. It operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The company develops, manufactures, and markets products primarily in the therapeutic areas of gastroenterology, hepatology, neurology and dermatology, generic and branded generic pharmaceuticals, dentistry products, over-the-counter products, aesthetic medical devices, and eye health. The company sells its products in the United States, China, Canada, Poland, Mexico, France, South Korea, Russia, Japan, Germany, the United Kingdom, Spain, Italy, and internationally. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.
Aktuelle News
-
Bausch Health's Ortho Dermatologics Announces the 2026 Aspire Higher Scholarship Winners
Vorschau anzeigen
Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, and its dermatology business, Ortho Dermatologics, today announced the recipients of its 2026 Aspire Higher Scholarship Program. Since launching in 2013, the program has awarded 87 scholarships, totaling over $1 million, to students who have been treated for dermatologic conditions. This year, six inspiring students will each receive up to $10,000 to support their undergraduate or graduate studies.
-
Bausch Health Announces 2026 Gastrointestinal Health Scholars Program Winners
Vorschau anzeigen
Bausch Health Companies Inc. (NYSE: BHC)(TSX: BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), today announced the recipients of its 2026 Salix Gastrointestinal Health Scholars Program. For the seventh year, Bausch Health is proud to award 10 deserving students living with a GI disease $10,000 each to further their higher education.
-
Why Bausch Health Companies Stock Skyrocketed by Almost 40% Last Month
Vorschau anzeigen
Much of this was due to a very well-received quarterly earnings report.
-
Bausch Health CEO Thomas J. Appio Joins Bausch + Lomb Board
Vorschau anzeigen
Bausch Health Companies Inc. (NYSE: BHC)(TSX: BHC) ("Bausch Health" or the "Company"), today announced that its CEO, Thomas J. Appio, has been appointed to the board of directors of Bausch + Lomb Corporation (NYSE: BLCO)(TSX: BLCO), a subsidiary of Bausch Health Companies Inc., effective August 5, 2026.
-
(Pr)ELIDEL® (pimecrolimus) cream Now Reimbursed Under Alberta's Public Drug Plan for Eligible Patients with Mild to Moderate Atopic Dermatitis
Vorschau anzeigen
Bausch Health, Canada Inc., a subsidiary of Bausch Health Companies Inc. (NYSE: BHC)(TSX: BHC) announces that PrELIDEL® (pimecrolimus) cream is now listed under Alberta's public drug plan for eligible patients.